 |
 |
|
|
 The following documents on Sativex® are available on the Bayer Canada website and are intended for use only by medical professionals and patients resident in Canada: • Sativex® Oromucosal Spray Fact Sheets • Dear Healthcare Professional Letters For enquiries regarding Sativex® please contact Bayer Canada, GW’s marketing partner in Canada: Tel: (1) 800 265 7382 |
|
| © GW Pharmaceuticals 2009 |
 |
- Home
- Corporate Information
Management Team-
- Management Team
- Board of Directors
- Committees of the Board
- Senior Management Team
- Job Vacancies
- Links
- Investor Relations
- Introduction
- Financial Performance
-
- Key Financial Data
- Reports & Accounts
- Share Price
- Share Charts
- Securities in Issue
- Press & News
-
- Press Releases
- RNS Announcements
- Shareholder Info
-
- FAQs
- Financial Calendar
- Shareholder Services
- Contacts
- Info Request
- News Alert
-
- Alert Service
- Presentations
- AIM Rule 26
- Research & Development
- Introduction
- Product Pipeline
- Intellectual Property Rights
- Cannabinoid Medications
-
- Cannabinoids
- Mechanism of Action
- Intoxication
- Sativex®
- Cultivation
- Clinical Trials Review
- Clinical Publications
- Cannabinoid ResearchInstitute (CRI)
- Advanced Dispensing System (ADS)
-
- Introduction to ADS
- Drug Addiction
- Other Applications of ADS
- FAQs
- News & Media
- Press Releases
- Notes for Editors
- Sativex®
- United States
- Contact Us
| Search | |
 |
 |
| Site Map |
| Privacy Statement |
| Disclosure & Disclaimer |